ASHBURN, Va., Feb. 1, 2012 /PRNewswire/ -- Innocoll Inc. announced it has entered into a License and Distribution Agreement with Flynn Pharma Ltd. in the United Kingdom and with Inresa Arzneimittel GmbH in Germany for CollaGUARD surgical adhesion barrier for the prevention of postoperative adhesions following abdominal and pelvic surgery.
Dr. Michael Myers, President and CEO stated, "We are pleased to announce these partnerships for two of the key markets in the EU and we look forward to a successful launch of this important product."
David Walters, Director of Flynn and Inresa commented, "We are delighted to be working with Innocoll on this innovative product which is consistent with, and complementary to, our model of adding products for the secondary healthcare markets."
CollaGUARD is a transparent bioresorbable film of 100% type I collagen developed using Innocoll's proprietary CollaFilm technology. It is approved in Europe for the prevention of postoperative adhesions in patients undergoing abdominopelvic laparotomy or laparoscopy. When tested in vivo, CollaGUARD increased the probability of remaining adhesion-free by more than six fold (P < 0.001) and significantly reduced the extent and severity of adhesions (P < 0.001).
CollaGUARD has been designed and engineered with a unique combination of features for optimal handling, ease-of-use, and anti-adhesion performance. It is highly stable at room temperature and does not require any advanced preparation before use. The product is non-tacky and can be easily rolled for insertion through a trocar when implanted laparoscopically. CollaGUARD is available in a wide variety of sizes up to 20 x 30 cm; it may be cut and sutured if required and therefore used efficiently across a broad range of surgeries.
Innocoll has entered into distribution partnerships for CollaGUARD in over 23 countries. For more information please visit www.CollaGUARD.com.
About Postoperative Adhesions
Postoperative adhesions are abnormal fibrous connections that can form between any apposing internal organ and serous membrane as a natural consequence of abdominopelvic surgery. Adhesions occur in almost 95% of laparotomies and may lead to serious complications such as intestinal obstruction, secondary female infertility, and chronic abdominal or pelvic pain. More than 30% of patients who undergo open gynecologic or general surgery are readmitted within 10 years for disorders that are considered directly or potentially related to adhesions, with an average of 2 readmissions per patient. In the United States, there are approximately 350,000 hospitalizations annually for adhesiolysis following gynecologic or abdominal surgery, which account for almost 1 million inpatient days at a cost of $2.3 billion. Even for patients without complications, adhesions originating from a previous surgery can present significant surgical challenges and additional morbidity risks in subsequent operations.
About Flynn Pharma.
Flynn Pharma Limited is a specialty pharmaceutical company focused on acquiring and commercializing proprietary products in secondary healthcare and related markets. Flynn's goal is to be the foremost European provider of specialty products in targeted and underserved therapeutic categories. In the last few years, Flynn has been restructured and financed to pursue an aggressive and rapid growth strategy in these sectors, offering superior customer service and value growth for our shareholders.
For additional information about Flynn visit the Company's website at www.flynnpharma.com.
About Innocoll, Inc.
Innocoll is a privately held, biopharmaceutical company focused on biodegradable surgical implants and topically applied healthcare products. The company develops and manufactures a range of pharmaceutical products and medical devices using its proprietary collagen-based technologies, CollaRx®, CollaFilm, DermaSil™, CollaPressTM and Liquicoll®. Approved products based on the Company's technologies include: Collatamp® G, Septocoll®, CollaGUARD, Collieva®, CollaCare®, Collexa®, Zorpreva™, and LidoColl®.
Other products in clinical and regulatory development include: CollaRx Gentamicin Surgical Implant in phase 3 for prevention of surgical wound infections, Cogenzia in phase 3 for the adjuvant treatment of infected diabetic foot ulcers, and Xaracoll in phase 3 for the management of post-operative pain. For more information, please visit www.innocollinc.com.
|SOURCE Innocoll, Inc.|
Copyright©2010 PR Newswire.
All rights reserved